340 related articles for article (PubMed ID: 34831189)
1. Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis.
Porras L; Ismail H; Mader S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831189
[TBL] [Abstract][Full Text] [Related]
2. Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Teinturier R; Abou Ziki R; Kassem L; Luo Y; Malbeteau L; Gherardi S; Corbo L; Bertolino P; Bachelot T; Treilleux I; Zhang CX; Le Romancer M
Breast Cancer Res Treat; 2021 Dec; 190(3):389-401. PubMed ID: 34561764
[TBL] [Abstract][Full Text] [Related]
3. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
5. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
6. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.
Irish JC; Mills JN; Turner-Ivey B; Wilson RC; Guest ST; Rutkovsky A; Dombkowski A; Kappler CS; Hardiman G; Ethier SP
Mol Oncol; 2016 Jun; 10(6):850-65. PubMed ID: 27005559
[TBL] [Abstract][Full Text] [Related]
7. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
8. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
9. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.
Theodorou V; Stark R; Menon S; Carroll JS
Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.
Bernardo GM; Lozada KL; Miedler JD; Harburg G; Hewitt SC; Mosley JD; Godwin AK; Korach KS; Visvader JE; Kaestner KH; Abdul-Karim FW; Montano MM; Keri RA
Development; 2010 Jun; 137(12):2045-54. PubMed ID: 20501593
[TBL] [Abstract][Full Text] [Related]
11. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
12. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.
Cao J; Wu D; Wu G; Wang Y; Ren T; Wang Y; Lv Y; Sun W; Wang J; Qian C; He L; Yang K; Li H; Gu H
Cell Death Dis; 2021 Jun; 12(6):619. PubMed ID: 34131114
[TBL] [Abstract][Full Text] [Related]
13. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
Tomita S; Zhang Z; Nakano M; Ibusuki M; Kawazoe T; Yamamoto Y; Iwase H
Cancer Sci; 2009 Jun; 100(6):1012-7. PubMed ID: 19320640
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.
Powers GL; Rajbhandari P; Solodin NM; Bickford B; Alarid ET
PLoS One; 2013; 8(12):e81110. PubMed ID: 24339902
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.
Stone A; Zotenko E; Locke WJ; Korbie D; Millar EK; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JM; Clark SJ
Nat Commun; 2015 Jul; 6():7758. PubMed ID: 26169690
[TBL] [Abstract][Full Text] [Related]
18. R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers.
Boldes T; Merenbakh-Lamin K; Journo S; Shachar E; Lipson D; Yeheskel A; Pasmanik-Chor M; Rubinek T; Wolf I
BMC Cancer; 2020 Jun; 20(1):531. PubMed ID: 32513126
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
20. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
